{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:49:56Z","timestamp":1787003396982,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T00:00:00Z","timestamp":1497225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T00:00:00Z","timestamp":1497225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Circulating plasma and peripheral blood mononuclear (PBMCs) cells provide an informative snapshot of the systemic physiological state. Moreover, they provide a non-invasively accessible compartment to identify biomarkers for personalized medicine in advanced breast cancer. The role of Neuropilin-1 (NRP-1) and its interacting molecules in breast tumor tissue was correlated with cancer progression; however, the clinical impact of their systemic levels was not extensively evaluated. In this cross-sectional study, we found that circulating and tumor tissue expression of NRP-1 and circulating placental growth factor (PlGF) increase in advanced nodal and metastatic breast cancer compared with locally advanced disease. Tumor tissue expression of NRP-1 and PlGF is also upregulated in triple negative breast cancer (TNBC) compared to other subtypes. Conversely, in PBMCs,\n                    <jats:italic>NRP-1<\/jats:italic>\n                    and its interacting molecules\n                    <jats:italic>SEMA4A<\/jats:italic>\n                    and\n                    <jats:italic>SNAI1<\/jats:italic>\n                    are significantly downregulated in breast cancer patients compared to healthy controls, indicating a protective role. Moreover, we report differential PBMC expression profiles that correlate inversely with disease stage (\n                    <jats:italic>SEMA4A, SNAI1, PLXNA1<\/jats:italic>\n                    and\n                    <jats:italic>VEGFR3<\/jats:italic>\n                    ) and can differentiate between the TNBC and non-TNBC tumor subtypes (\n                    <jats:italic>VEGFR3<\/jats:italic>\n                    and\n                    <jats:italic>PLXNA1<\/jats:italic>\n                    ). This work supports the importance of NRP-1-associated molecules in circulation to characterize poor prognosis breast cancer and emphasizes on their role as favorable drug targets.\n                  <\/jats:p>","DOI":"10.1038\/s41598-017-03280-0","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T09:32:01Z","timestamp":1496741521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Neuropilin-1 Associated Molecules in the Blood Distinguish Poor Prognosis Breast Cancer: A Cross-Sectional Study"],"prefix":"10.1038","volume":"7","author":[{"given":"Adviti","family":"Naik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"Al-Zeheimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Saki","family":"Bakheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Al Riyami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Al Jarrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour S.","family":"Al Moundhri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zamzam","family":"Al Habsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysoon","family":"Basheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirin A.","family":"Adham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,12]]},"reference":[{"key":"3280_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. \n                           66, 7\u201330, doi:10.3322\/caac.21332 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"3280_CR2","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1200\/JCO.2014.55.4139","volume":"32","author":"GW Sledge","year":"2014","unstructured":"Sledge, G. W. et al. Past, Present, and Future Challenges in Breast Cancer Treatment. J. Clin. Oncol. \n                           32, 1979\u20131986, doi:10.1200\/jco.2014.55.4139 (2014).","journal-title":"J. Clin. Oncol."},{"key":"3280_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1074\/mcp.R200007-MCP200","volume":"1","author":"NL Anderson","year":"2002","unstructured":"Anderson, N. L. The Human Plasma Proteome: History, Character, and Diagnostic Prospects. Mol. Cell. Proteomics \n                           1, 845\u2013867, doi:10.1074\/mcp.r200007-mcp200 (2002).","journal-title":"Mol. Cell. Proteomics"},{"key":"3280_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, Inflammation, and Cancer. Cell \n                           140, 883\u2013899, doi:10.1016\/j.cell.2010.01.025 (2010).","journal-title":"Cell"},{"key":"3280_CR5","doi-asserted-by":"publisher","unstructured":"Baine, M. J., Mallya, K. & Batra, S. K. Quantitative Real-Time PCR Expression Analysis of Peripheral Blood Mononuclear Cells in Pancreatic Cancer Patients. Methods Mol. Biol., 157\u2013173, doi:10.1007\/978-1-62703-287-2_8 (2012).","DOI":"10.1007\/978-1-62703-287-2_8"},{"key":"3280_CR6","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/labinvest.2015.88","volume":"95","author":"J Ma","year":"2015","unstructured":"Ma, J. et al. Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer. Lab. Invest. \n                           95, 1197\u20131206, doi:10.1038\/labinvest.2015.88 (2015).","journal-title":"Lab. Invest."},{"key":"3280_CR7","first-page":"6069","volume":"63","author":"NC Twine","year":"2003","unstructured":"Twine, N. C. et al. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res. \n                           63, 6069\u20136075 (2003).","journal-title":"Cancer Res."},{"key":"3280_CR8","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0022-5347(05)00564-1","volume":"175","author":"ME Burczynski","year":"2006","unstructured":"Burczynski, M. E. et al. Transcriptional Profiles in Peripheral Blood Mononuclear Cells Prognostic of Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. J. Urol. \n                           175, 892\u2013893, doi:10.1016\/s0022-5347(05)00564-1 (2006).","journal-title":"J. Urol."},{"key":"3280_CR9","doi-asserted-by":"publisher","first-page":"24818","DOI":"10.1074\/jbc.M200730200","volume":"277","author":"R Mamluk","year":"2002","unstructured":"Mamluk, R. et al. Neuropilin-1 Binds Vascular Endothelial Growth Factor 165, Placenta Growth Factor-2, and Heparin via Its b1b2 Domain. J. Biol. Chem. \n                           277, 24818\u201324825, doi:10.1074\/jbc.m200730200 (2002).","journal-title":"J. Biol. Chem."},{"key":"3280_CR10","doi-asserted-by":"publisher","first-page":"13493","DOI":"10.1074\/jbc.M512121200","volume":"281","author":"H Jia","year":"2006","unstructured":"Jia, H. et al. Characterization of a Bicyclic Peptide Neuropilin-1 (NP-1) Antagonist (EG3287) Reveals Importance of Vascular Endothelial Growth Factor Exon 8 for NP-1 Binding and Role of NP-1 in KDR Signaling. J. Biol. Chem. \n                           281, 13493\u201313502, doi:10.1074\/jbc.m512121200 (2006).","journal-title":"J. Biol. Chem."},{"key":"3280_CR11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/carcin\/bgq281","volume":"32","author":"Y Glinka","year":"2010","unstructured":"Glinka, Y., Stoilova, S., Mohammed, N. & Prud\u2019homme, G. J. Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. Carcinogenesis \n                           32, 613\u2013621, doi:10.1093\/carcin\/bgq281 (2010).","journal-title":"Carcinogenesis"},{"key":"3280_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ygeno.2004.02.001","volume":"84","author":"FC Cackowski","year":"2004","unstructured":"Cackowski, F. C., Xu, L., Hu, B. & Cheng, S.-Y. Identification of two novel alternatively spliced Neuropilin-1 isoforms. Genomics \n                           84, 82\u201394, doi:10.1016\/j.ygeno.2004.02.001 (2004).","journal-title":"Genomics"},{"key":"3280_CR13","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.1158\/1078-0432.CCR-12-1652","volume":"18","author":"Y Xin","year":"2012","unstructured":"Xin, Y. et al. Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors. Clin. Cancer. Res. \n                           18, 6040\u20136048, doi:10.1158\/1078-0432.ccr-12-1652 (2012).","journal-title":"Clin. Cancer. Res."},{"key":"3280_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1161\/ATVBAHA.114.304881","volume":"35","author":"Y Deng","year":"2015","unstructured":"Deng, Y., Zhang, X. & Simons, M. Molecular controls of lymphatic VEGFR3 signaling. Atertio. Thromb. Vasc. Biol. \n                           35, 421\u2013429 (2015).","journal-title":"Atertio. Thromb. Vasc. Biol."},{"key":"3280_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ccr.2012.06.031","volume":"22","author":"L Tamagnone","year":"2012","unstructured":"Tamagnone, L. Emerging Role of Semaphorins as Major Regulatory Signals and Potential Therapeutic Targets in Cancer. Cancer Cell \n                           22, 145\u2013152, doi:10.1016\/j.ccr.2012.06.031 (2012).","journal-title":"Cancer Cell"},{"key":"3280_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature12428","volume":"501","author":"GM Delgoffe","year":"2013","unstructured":"Delgoffe, G. M. et al. Stability and function of regulatory T cells is maintained by a neuropilin-1\u2013semaphorin-4a axis. Nature \n                           501, 252\u2013256, doi:10.1038\/nature12428 (2013).","journal-title":"Nature"},{"key":"3280_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ccr.2010.02.030","volume":"17","author":"P Mak","year":"2010","unstructured":"Mak, P. et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell \n                           17, 319\u2013332, doi:10.1016\/j.ccr.2010.02.030 (2010).","journal-title":"Cancer Cell"},{"key":"3280_CR18","doi-asserted-by":"publisher","unstructured":"Kaufhold, S. & Bonavida, B. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J. Exp. Clin. Cancer Res. 33, doi:10.1186\/s13046-014-0062-0 (2014).","DOI":"10.1186\/s13046-014-0062-0"},{"key":"3280_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1369\/0022155414538821","volume":"62","author":"SA Adham","year":"2014","unstructured":"Adham, S. A. et al. Immunohistological insight into the correlation between neuropilin-1 and epithelial-mesenchymal transition markers in epithelial ovarian cancer. J. Histochem. Cytochem. \n                           62, 619\u2013631, doi:10.1369\/0022155414538821 (2014).","journal-title":"J. Histochem. Cytochem."},{"key":"3280_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00262-013-1500-0","volume":"63","author":"B Chaudhary","year":"2013","unstructured":"Chaudhary, B., Khaled, Y. S., Ammori, B. J. & Elkord, E. Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol., Immunother. \n                           63, 81\u201399, doi:10.1007\/s00262-013-1500-0 (2013).","journal-title":"Cancer Immunol., Immunother."},{"key":"3280_CR21","doi-asserted-by":"publisher","unstructured":"Tordjman, R. et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat. Immunol., doi:10.1038\/ni789 (2002).","DOI":"10.1038\/ni789"},{"key":"3280_CR22","doi-asserted-by":"publisher","unstructured":"Wang, L. et al. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Med. 13, doi:10.1186\/s12916-015-0442-0 (2015).","DOI":"10.1186\/s12916-015-0442-0"},{"key":"3280_CR23","doi-asserted-by":"publisher","first-page":"e0123904","DOI":"10.1371\/journal.pone.0123904","volume":"10","author":"L Ciarloni","year":"2015","unstructured":"Ciarloni, L. et al. Discovery of a 29-Gene Panel in Peripheral Blood Mononuclear Cells for the Detection of Colorectal Cancer and Adenomas Using High Throughput Real-Time PCR. PLoS One \n                           10, e0123904, doi:10.1371\/journal.pone.0123904 (2015).","journal-title":"PLoS One"},{"key":"3280_CR24","doi-asserted-by":"publisher","first-page":"e102764","DOI":"10.1371\/journal.pone.0102764","volume":"9","author":"O Tudoran","year":"2014","unstructured":"Tudoran, O. et al. Differential Peripheral Blood Gene Expression Profile Based on Her2 Expression on Primary Tumors of Breast Cancer Patients. PLoS One \n                           9, e102764, doi:10.1371\/journal.pone.0102764 (2014).","journal-title":"PLoS One"},{"key":"3280_CR25","doi-asserted-by":"publisher","unstructured":"Przybyl, J. et al. Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications. Med. Oncol. 31, doi:10.1007\/s12032-014-0109-2 (2014).","DOI":"10.1007\/s12032-014-0109-2"},{"key":"3280_CR26","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1158\/1535-7163.MCT-05-0538","volume":"5","author":"LM Ellis","year":"2006","unstructured":"Ellis, L. M. The role of neuropilins in cancer. Mol. Cancer Ther. \n                           5, 1099\u20131107, doi:10.1158\/1535-7163.mct-05-0538 (2006).","journal-title":"Mol. Cancer Ther."},{"key":"3280_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2016.01.010","volume":"373","author":"M Luo","year":"2016","unstructured":"Luo, M. et al. VEGF\/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-\u03baB and \u03b2-catenin. Cancer Lett. \n                           373, 1\u201311, doi:10.1016\/j.canlet.2016.01.010 (2016).","journal-title":"Cancer Lett."},{"key":"3280_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12918-015-0201-z","volume":"9","author":"RJ Bender","year":"2015","unstructured":"Bender, R. J. & Mac Gabhann, F. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis. BMC Syst. Biol. \n                           9, 55, doi:10.1186\/s12918-015-0201-z (2015).","journal-title":"BMC Syst. Biol."},{"key":"3280_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10549-012-1957-0","volume":"133","author":"E Maae","year":"2012","unstructured":"Maae, E. et al. Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res. Treat. \n                           133, 257\u2013265, doi:10.1007\/s10549-012-1957-0 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"3280_CR30","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1016\/j.ejca.2005.07.022","volume":"41","author":"C Parr","year":"2005","unstructured":"Parr, C., Watkins, G., Boulton, M., Cai, J. & Jiang, W. G. Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur. J. Cancer \n                           41, 2819\u20132827, doi:10.1016\/j.ejca.2005.07.022 (2005).","journal-title":"Eur. J. Cancer"},{"key":"3280_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4318\/tjg.2012.0333","volume":"23","author":"O Kemik","year":"2012","unstructured":"Kemik, O. et al. Preoperative serum placenta growth factor level as a new marker for stage II or III colorectal cancer patients. Turk. J. Gastroenterol. \n                           23, 104\u2013109, doi:10.4318\/tjg.2012.0333 (2012).","journal-title":"Turk. J. Gastroenterol."},{"key":"3280_CR32","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1007\/DCR.0b013e3181afbdaf","volume":"52","author":"S-C Wei","year":"2009","unstructured":"Wei, S.-C. et al. Preoperative Serum Placenta Growth Factor Level Is a Prognostic Biomarker in Colorectal Cancer. Dis. Colon Rectum \n                           52, 1630\u20131636, doi:10.1007\/dcr.0b013e3181afbdaf (2009).","journal-title":"Dis. Colon Rectum"},{"key":"3280_CR33","doi-asserted-by":"publisher","first-page":"12133","DOI":"10.1038\/srep12133","volume":"5","author":"EJ Fertig","year":"2015","unstructured":"Fertig, E. J., Lee, E., Pandey, N. B. & Popel, A. S. Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes. Sci. Rep. \n                           5, 12133, doi:10.1038\/srep12133 (2015).","journal-title":"Sci. Rep."},{"key":"3280_CR34","doi-asserted-by":"publisher","first-page":"934","DOI":"10.4049\/jimmunol.1403038","volume":"195","author":"D Ito","year":"2015","unstructured":"Ito, D. et al. mTOR Complex Signaling through the SEMA4A-Plexin B2 Axis Is Required for Optimal Activation and Differentiation of CD8+ T Cells. J. Immunol. \n                           195, 934\u2013943, doi:10.4049\/jimmunol.1403038 (2015).","journal-title":"J. Immunol."},{"key":"3280_CR35","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1245\/ASO.2005.04.010","volume":"12","author":"TA Martin","year":"2005","unstructured":"Martin, T. A., Goyal, A., Watkins, G. & Jiang, W. G. Expression of the Transcription Factors Snail, Slug, and Twist and Their Clinical Significance in Human Breast Cancer. Ann. Surg. Oncol. \n                           12, 488\u2013496, doi:10.1245\/aso.2005.04.010 (2005).","journal-title":"Ann. Surg. Oncol."},{"key":"3280_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0960-0760(02)00276-5","volume":"83","author":"S Chen","year":"2002","unstructured":"Chen, S., Itoh, T., Wu, K., Zhou, D. & Yang, C. Transcriptional regulation of aromatase expression in human breast tissue. J. Steroid Biochem. Mol. Biol. \n                           83, 93\u201399, doi:10.1016\/s0960-0760(02)00276-5 (2002).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"3280_CR37","doi-asserted-by":"publisher","first-page":"e0134990","DOI":"10.1371\/journal.pone.0134990","volume":"10","author":"X Niu","year":"2015","unstructured":"Niu, X. et al. The Crosstalk of Pathways Involved in Immune Response Maybe the Shared Molecular Basis of Rheumatoid Arthritis and Type 2 Diabetes. PLoS One \n                           10, e0134990, doi:10.1371\/journal.pone.0134990 (2015).","journal-title":"PLoS One"},{"key":"3280_CR38","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.it.2004.05.003","volume":"25","author":"P Saharinen","year":"2004","unstructured":"Saharinen, P., Tammela, T., Karkkainen, M. J. & Alitalo, K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. \n                           25, 387\u2013395, doi:10.1016\/j.it.2004.05.003 (2004).","journal-title":"Trends Immunol."},{"key":"3280_CR39","doi-asserted-by":"publisher","first-page":"e61788","DOI":"10.1371\/journal.pone.0061788","volume":"8","author":"RJ Bender","year":"2013","unstructured":"Bender, R. J. & Mac Gabhann, F. Expression of VEGF and Semaphorin Genes Define Subgroups of Triple Negative Breast Cancer. PLoS One \n                           8, e61788, doi:10.1371\/journal.pone.0061788 (2013).","journal-title":"PLoS One"},{"key":"3280_CR40","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Teijido, P., Pelaez-Fern\u00e1ndez, I., Fern\u00e1ndez-P\u00e9rez, Y. & Luque-Cabal, M. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clin. Med. Insights Oncol. 31, doi:10.4137\/cmo.s34540 (2016).","DOI":"10.4137\/cmo.s34540"},{"key":"3280_CR41","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.14694\/EdBook_AM.2015.35.e25","volume":"35","author":"ML Disis","year":"2015","unstructured":"Disis, M. L. & Stanton, S. E. Triple-Negative Breast Cancer: Immune Modulation as the New Treatment Paradigm. Am. Soc. Clin. Oncol. Educ. Book \n                           35, e25\u2013e30, doi:10.14694\/edbook_am.2015.35.e25 (2015).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"3280_CR42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrc3246","volume":"12","author":"T Blankenstein","year":"2012","unstructured":"Blankenstein, T., Coulie, P. G., Gilboa, E. & Jaffee, E. M. The determinants of tumour immunogenicity. Nat. Rev. Cancer \n                           12, 307\u2013313, doi:10.1038\/nrc3246 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"3280_CR43","doi-asserted-by":"crossref","unstructured":"Kleiveland, C. R. In The Impact of Food Bioactives on Health: in vitro and ex vivo models (eds Kitty Verhoeckx et al.) 161\u2013167 (Springer International Publishing, 2015).","DOI":"10.1007\/978-3-319-16104-4_15"},{"key":"3280_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-011-0202-z","volume":"14","author":"AJ Montero","year":"2011","unstructured":"Montero, A. J., Escobar, M., Lopes, G., Gl\u00fcck, S. & Vogel, C. Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe? Curr. Oncol. Rep. \n                           14, 1\u201311, doi:10.1007\/s11912-011-0202-z (2011).","journal-title":"Curr. Oncol. Rep."},{"key":"3280_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccr.2006.10.018","volume":"11","author":"Q Pan","year":"2007","unstructured":"Pan, Q. et al. Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth. Cancer Cell \n                           11, 53\u201367, doi:10.1016\/j.ccr.2006.10.018 (2007).","journal-title":"Cancer Cell"},{"key":"3280_CR46","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10637-014-0071-z","volume":"32","author":"CD Weekes","year":"2014","unstructured":"Weekes, C. D. et al. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest. New Drugs \n                           32, 653\u2013660, doi:10.1007\/s10637-014-0071-z (2014).","journal-title":"Invest. New Drugs"},{"key":"3280_CR47","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00280-014-2426-8","volume":"73","author":"A Patnaik","year":"2014","unstructured":"Patnaik, A. et al. A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. \n                           73, 951\u2013960, doi:10.1007\/s00280-014-2426-8 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"3280_CR48","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cell.2007.08.038","volume":"131","author":"C Fischer","year":"2007","unstructured":"Fischer, C. et al. Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels. Cell \n                           131, 463\u2013475, doi:10.1016\/j.cell.2007.08.038 (2007).","journal-title":"Cell"},{"key":"3280_CR49","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cell.2010.02.039","volume":"141","author":"S Van de Veire","year":"2010","unstructured":"Van de Veire, S. et al. Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease. Cell \n                           141, 178\u2013190, doi:10.1016\/j.cell.2010.02.039 (2010).","journal-title":"Cell"},{"key":"3280_CR50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s12094-013-1058-5","volume":"16","author":"Y K\u0131l\u0131\u00e7","year":"2013","unstructured":"K\u0131l\u0131\u00e7, Y., \u00c7elebiler, A. \u00c7. & Sak\u0131zl\u0131, M. Selecting housekeeping genes as references for the normalization of quantitative PCR data in breast cancer. Clin. Transl. Oncol. \n                           16, 184\u2013190, doi:10.1007\/s12094-013-1058-5 (2013).","journal-title":"Clin. Transl. Oncol."},{"key":"3280_CR51","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.bbrc.2003.12.175","volume":"314","author":"T Yonezawa","year":"2004","unstructured":"Yonezawa, T., Katoh, K. & Obara, Y. Existence of GPR40 functioning in a human breast cancer cell line, MCF-7. Biochem. Biophys. Res. Commun. \n                           314, 805\u2013809, doi:10.1016\/j.bbrc.2003.12.175 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3280_CR52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.oraloncology.2008.03.019","volume":"45","author":"MS Campos","year":"2009","unstructured":"Campos, M. S., Rodini, C. O., Pinto-J\u00fanior, D. S. & Nunes, F. D. GAPD and tubulin are suitable internal controls for qPCR analysis of oral squamous cell carcinoma cell lines. Oral Oncol. \n                           45, 121\u2013126, doi:10.1016\/j.oraloncology.2008.03.019 (2009).","journal-title":"Oral Oncol."},{"key":"3280_CR53","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ab.2009.07.022","volume":"394","author":"Y-L Li","year":"2009","unstructured":"Li, Y.-L., Ye, F., Hu, Y., Lu, W.-G. & Xie, X. Identification of suitable reference genes for gene expression studies of human serous ovarian cancer by real-time polymerase chain reaction. Anal. Biochem. \n                           394, 110\u2013116, doi:10.1016\/j.ab.2009.07.022 (2009).","journal-title":"Anal. Biochem."},{"key":"3280_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2199-10-17","volume":"10","author":"V Valente","year":"2009","unstructured":"Valente, V. et al. Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR. BMC Mol. Biol. \n                           10, 17, doi:10.1186\/1471-2199-10-17 (2009).","journal-title":"BMC Mol. Biol."},{"key":"3280_CR55","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.bbrc.2003.11.177","volume":"313","author":"A Radoni\u0107","year":"2004","unstructured":"Radoni\u0107, A. et al. Guideline to reference gene selection for quantitative real-time PCR. Biochem. Biophys. Res. Commun. \n                           313, 856\u2013862, doi:10.1016\/j.bbrc.2003.11.177 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3280_CR56","doi-asserted-by":"publisher","first-page":"research0034.00","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. \n                           3, research0034.0031, doi:10.1186\/gb-2002-3-7-research0034 (2002).","journal-title":"Genome Biol."},{"key":"3280_CR57","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/bjc.1996.236","volume":"73","author":"X Chui","year":"1996","unstructured":"Chui, X. et al. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br. J. Cancer \n                           73, 1233\u20131236 (1996).","journal-title":"Br. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03280-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03280-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03280-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:15:09Z","timestamp":1671754509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03280-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,12]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["3280"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-03280-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,12]]},"assertion":[{"value":"12 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3301"}}